logo-loader
Acasti Pharma Inc.

Acasti Pharma Inc receives new patents in Israel, Mexico and Chile as it advances its cardiovascular drug

The company's flagship drug CaPre is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis

vials of blood
CaPre is primarily composed of certain omega-3 fatty acids that are thought to contribute to promote healthy heart, brain and visual function

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has been granted patents related to the development of its prescription drug candidate CaPre in Israel, Mexico and Chile, the pharmaceutical company announced Wednesday.

CaPre is being developed to treat severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis.

Derived from krill oil, CaPre is primarily composed of certain omega-3 fatty acids that are thought to contribute to promote healthy heart, brain and visual function by reducing inflammation and types of fat known as triglycerides. Hypertriglyceridemia is an elevated level of that fat, or lipids, found in the blood.

READ: Ventripoint Diagnostics to bring its cardiac-imaging technology to France

The new patents, which are valid until 2030, relate to a concentrated phospholipid composition and method of using the same for modulating blood lipids, the company said in a statement.

“We are pleased to announce the granting of these latest patents, which further strengthen and expand the Acasti’s intellectual property portfolio,” said Pierre Lemieux, COO and CSO of Acasti.

According to Acasti, Israel, Mexico and Chile each represent important markets for potential commercialization of CaPre.

“The granting of these patents is another important milestone for Acasti and is in line with our commitment to build a global portfolio of patents to ensure long-lasting and comprehensive protection of our products,” Lemieux said in a statement.

Phase 3 testing underway

Phase 3 testing of CaPre is currently underway and will evaluate the safety and efficacy of the drug for the treatment of patients with severe hypertriglyceridemia. The study is a double-blind, placebo-controlled, 26-week, two-trial Phase 3 clinical program. Phase 1 and 2 are running in conjunction and will randomize a total of approximately 500 patients.

The program is being conducted at approximately 150 sites across the U.S., Canada and Mexico. Acasti anticipates reporting topline results by the end of 2019.

Shares of Acasti were trading at C$1.08 in Toronto and at US$0.81 in the US on Wednesday morning.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Acasti Pharma Inc.

Price: $2.38

Market: TSX-V
Market Cap: $201.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc. named herein, including the promotion by the Company of Acasti Pharma Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Acasti Pharma gets new Chinese patent that paves the way for its heart...

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) Co-Founder and COO Pierre Lemieux tells Proactive Investors it was awarded a second patent in China covering its flagship drug candidate CaPre, an omega-3 phospholipid. Lemieux says currently in China there is no approved drug like CaPre, where...

on 26/6/19

2 min read